​

AstraZeneca (AZN) Stock Forecast, Price Target & Predictions

OverviewOwnershipChartTranscripts

AZN Stock Forecast

AstraZeneca (AZN) stock forecast, based on 41 Wall Street analysts, predicts a 12-month average price target of $102.67, with a high of $108.00 and a low of $97.00. This represents a 13.71% increase from the last price of $90.29.

$60 $70 $80 $90 $100 $110 High: $108 Avg: $102.67 Low: $97 Last Closed Price: $90.29

AZN Stock Rating

AstraZeneca stock's rating consensus is Buy, based on 41 Wall Street analysts. The breakdown includes 1 Strong Buy (2.44%), 19 Buy (46.34%), 15 Hold (36.59%), 6 Sell (14.63%), and 0 Strong Sell (0.00%).

Buy
Total 41 6 15 19 1 Strong Sell Sell Hold Buy Strong Buy

AZN Price Target Upside V Benchmarks

TypeNameUpside
StockAstraZeneca13.71%
SectorHealthcare Stocks 15.45%
IndustryDrug Manufacturers - General Stocks7.11%

Price Target Trends

1M3M12M
# Anlaysts223
Avg Price Target$105.50$105.50$102.67
Last Closing Price$90.29$90.29$90.29
Upside/Downside16.85%16.85%13.71%
Ratings Trends
DateStrong BuyBuyHoldSellStrong SellTotal
Dec, 25281--11
Nov, 25281--11
Oct, 25262--10
Sep, 25272--11
Aug, 25272--11
Analyst Price Target Forecasts
DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
Dec 10, 2025HSBC$108.00$89.8220.24%19.61%
Dec 03, 2025Morgan Stanley$103.00$90.1714.23%14.08%
Jul 09, 2025Luisa HectorBerenberg Bank$97.00$70.8236.97%7.43%
Nov 13, 2024Etzer DaroutBMO Capital$88.00$81.198.39%-2.54%
Sep 11, 2024Etzer DaroutBMO Capital$89.00$79.9411.33%-1.43%
May 30, 2024John EadeArgus Research$85.00$76.8410.62%-5.86%
May 28, 2024Etzer DaroutBMO Capital$82.00$76.746.85%-9.18%
Jul 12, 2023Andrew BerensLeerink Partners$79.00$64.8621.80%-12.50%
Jan 05, 2023BMO Capital$82.00$69.5017.99%-9.18%
Nov 11, 2022Leerink Partners$78.00$65.0919.83%-13.61%
Analyst Rating Forecasts
DateCompanyPrevious RatingNew RatingRating Change
Dec 10, 2025HSBCBuyBuyhold
Dec 09, 2025Cowen & Co.BuyBuyhold
Dec 03, 2025GuggenheimBuyBuyhold
Dec 03, 2025Morgan StanleyOverweightOverweighthold
Nov 25, 2025Bank of America SecuritiesBuyBuyhold
Nov 13, 2024BMO CapitalOutperformOutperformhold
Sep 13, 2024Deutsche BankSellHolddowngrade
Sep 12, 2024Deutsche BankHoldSelldowngrade
Sep 11, 2024BMO CapitalOutperformOutperformhold
Sep 11, 2024NordeaSelldowngrade

Financial Forecast

EPS Forecast

$0 $1 $2 $3 $4 $5 $6 $7 Dec 20 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 20Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$1.22$0.04$1.06------
Avg Forecast$2.09$2.59$3.36$3.67$4.11$4.63$5.15$5.70$6.10
High Forecast$2.16$2.68$3.47$3.80$4.26$5.25$5.69$6.42$6.34
Low Forecast$2.01$2.49$3.16$3.58$4.05$4.40$4.57$5.25$5.85
Surprise %-41.63%-98.46%-68.45%------

Revenue Forecast

$25B $34B $43B $52B $61B $70B Dec 20 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 20Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$26.62B$37.42B$44.35B$45.81B-----
Avg Forecast$26.38B$36.41B$44.44B$45.81B$53.22B$56.79B$60.50B$64.28B$67.65B
High Forecast$27.02B$37.30B$45.54B$45.98B$53.59B$57.53B$60.61B$64.51B$69.72B
Low Forecast$25.56B$35.28B$42.41B$45.67B$52.69B$55.85B$60.39B$64.05B$65.51B
Surprise %0.91%2.76%-0.20%-0.00%-----

Net Income Forecast

$-5B $1B $7B $13B $19B $25B Dec 20 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 20Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$3.20B$112.00M$3.29B$5.96B-----
Avg Forecast$3.19B$-238.15M$-1.38B$5.96B$12.99B$15.08B$16.02B$18.22B$19.05B
High Forecast$3.83B$595.60M$-689.41M$8.94B$13.32B$16.40B$17.78B$20.04B$19.81B
Low Forecast$2.55B$-1.07B$-2.08B$2.97B$12.66B$13.76B$14.27B$16.40B$18.26B
Surprise %0.13%-147.03%-337.84%------

AZN Forecast FAQ

Is AstraZeneca stock a buy?

AstraZeneca stock has a consensus rating of Buy, based on 41 Wall Street analysts. The rating breakdown includes 1 Strong Buy, 19 Buy, 15 Hold, 6 Sell, and 0 Strong Sell, reflecting a consensus that AstraZeneca is a favorable investment for most analysts.

What is AstraZeneca's price target?

AstraZeneca's price target, set by 41 Wall Street analysts, averages $102.67 over the next 12 months. The price target range spans from $97 at the low end to $108 at the high end, suggesting a potential 13.71% change from the previous closing price of $90.29.

How does AstraZeneca stock forecast compare to its benchmarks?

AstraZeneca's stock forecast shows a 13.71% upside, underperforming the average forecast for the healthcare stocks sector (15.45%) and outperforming the drug manufacturers - general stocks industry (7.11%).

What is the breakdown of analyst ratings for AstraZeneca over the past three months?

  • December 2025: 18.18% Strong Buy, 72.73% Buy, 9.09% Hold, 0% Sell, 0% Strong Sell.
  • November 2025: 18.18% Strong Buy, 72.73% Buy, 9.09% Hold, 0% Sell, 0% Strong Sell.
  • October 2025: 20.00% Strong Buy, 60.00% Buy, 20.00% Hold, 0% Sell, 0% Strong Sell.

What is AstraZeneca’s EPS forecast?

AstraZeneca's average annual EPS forecast for its fiscal year ending in December 2024 is $4.11, marking a 0% decrease from the reported $0 in 2023. Estimates for the following years are $4.63 in 2025, $5.15 in 2026, $5.7 in 2027, and $6.1 in 2028.

What is AstraZeneca’s revenue forecast?

AstraZeneca's average annual revenue forecast for its fiscal year ending in December 2024 is $53.22B, reflecting a 16.18% increase from the reported $45.81B in 2023. The forecast for 2025 is $56.79B, followed by $60.5B for 2026, $64.28B for 2027, and $67.65B for 2028.

What is AstraZeneca’s net income forecast?

AstraZeneca's net income forecast for the fiscal year ending in December 2024 stands at $12.99B, representing an 118.12% increase from the reported $5.96B in 2023. Projections indicate $15.08B in 2025, $16.02B in 2026, $18.22B in 2027, and $19.05B in 2028.